Literature DB >> 10821991

Carvedilol affects the physiological and behavioral response to smoked cocaine in humans.

M Sofuoglu1, S Brown, D A Babb, P R Pentel, D K Hatsukami.   

Abstract

The noradrenergic system is implicated in mediating some of the physiological effects of cocaine. The purpose of this study was to investigate whether treatment with an adrenergic blocker, carvedilol, which would be expected to attenuate the physiological effects of cocaine, would also attenuate the subjective and behavioral response to cocaine in humans. Twelve crack cocaine users participated in this double-blind, placebo-controlled outpatient study. Acute treatment with 50 mg of oral carvedilol attenuated the smoked cocaine-induced increases in heart rate, systolic and diastolic blood pressure. The number of cocaine self-administrations was lower under 25 mg carvedilol treatment condition compared with 50 mg carvedilol or placebo treatment conditions. The subjective responses to smoked cocaine deliveries were not affected by carvedilol treatment. These results suggest that acute treatment with carvedilol attenuates the physiological effects of smoked cocaine. The effects of carvedilol on cocaine self-administration need to be studied further.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821991     DOI: 10.1016/s0376-8716(99)00143-x

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  20 in total

1.  Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.

Authors:  Cm Hysek; Y Schmid; A Rickli; L D Simmler; M Donzelli; E Grouzmann; M E Liechti
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 2.  Rethinking cocaine-associated chest pain and acute coronary syndromes.

Authors:  Jonathan B Finkel; Gregary D Marhefka
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

Review 3.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

4.  Involvement of noradrenergic neurotransmission in the stress- but not cocaine-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: role for β-2 adrenergic receptors.

Authors:  John R Mantsch; Andy Weyer; Oliver Vranjkovic; Chad E Beyer; David A Baker; Holly Caretta
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

Review 5.  A qualitative and quantitative review of cocaine-induced craving: the phenomenon of priming.

Authors:  James J Mahoney; Ari D Kalechstein; Richard De La Garza; Thomas F Newton
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-01-31       Impact factor: 5.067

Review 6.  Impact of gender on corticotropin-releasing factor and noradrenergic sensitivity in cocaine use disorder.

Authors:  Aimee L McRae-Clark; Angie M Cason; Amy S Kohtz; Megan Moran Santa-Maria; Gary Aston-Jones; Kathleen T Brady
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

Review 7.  Novel approaches to the treatment of cocaine addiction.

Authors:  Mehmet Sofuoglu; Thomas R Kosten
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 8.  Norepinephrine and stimulant addiction.

Authors:  Mehmet Sofuoglu; R Andrew Sewell
Journal:  Addict Biol       Date:  2008-09-22       Impact factor: 4.280

9.  The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers.

Authors:  R De La Garza; J J Mahoney; C Culbertson; S Shoptaw; T F Newton
Journal:  Pharmacol Biochem Behav       Date:  2008-01-22       Impact factor: 3.533

10.  The search for medications to treat stimulant dependence.

Authors:  Kyle M Kampman
Journal:  Addict Sci Clin Pract       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.